Futura Medical plc (LON:FUM – Get Free Report)’s stock price traded down 10.2% on Tuesday. The company traded as low as GBX 0.18 and last traded at GBX 0.21. Approximately 15,721,019 shares traded hands during trading, an increase of 39% from the average daily volume of 11,277,613 shares. The stock had previously closed at GBX 0.24.
Futura Medical Price Performance
The firm’s 50 day moving average is GBX 0.21 and its 200 day moving average is GBX 0.66. The company has a market capitalization of £3.14 million, a PE ratio of -0.26 and a beta of 0.02.
Futura Medical (LON:FUM – Get Free Report) last released its quarterly earnings data on Tuesday, September 1st. The company reported GBX (0.20) earnings per share for the quarter. Futura Medical had a negative return on equity of 152.42% and a negative net margin of 158.21%. As a group, analysts predict that Futura Medical plc will post 2.85 EPS for the current fiscal year.
About Futura Medical
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products. Sexual health issues are prevalent in both men and women. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Recommended Stories
- Five stocks we like better than Futura Medical
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Futura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Futura Medical and related companies with MarketBeat.com's FREE daily email newsletter.
